Reproduction malignancies, including breast cancer, cervical cancer, ovarian cancer and endometrial cancer, have been one of the major causes of death in females, among which, breast cancer is the most common malignancy and the leading cause of cancer death in western countries. With an increasing incidence, reproduction malignancies have seriously affected living quality and health of the patients. It is estimated that there were 1.7 million new cases, causing 521,900 deaths throughout the world in 2012[@b1]. In China, with 268.6 thousand new cases, breast cancer accounts for 15% of all the new cases of cancers in 2015. Moreover, cervical and ovarian cancers are predicted to cause 30.5 thousand and 22.5 thousand deaths in Chinese female respectively according to the latest cancer statistics[@b2]. Although nowadays medical treatment is advanced, the prognosis of reproduction malignancies patients is dismal, and metastasis is still the major cause of death. In addition, there lacks appropriate indicator which can effectively predict the prognosis of reproduction malignancies patients. Therefore, it is urgent to seek an impeccable marker which can reflect the status of metastasis and clinical survival outcomes for patients with reproduction malignancies.

Recently, researchers have made great efforts to explore new biomarkers which are associated with the diagnosis, progression and prognosis of reproduction malignancies. Metadherin (MTDH), as a cell surface protein, could induce breast cancer cells transferring to lung in mouse model. Its gene, astrocyte elevated gene-1 (AEG-1), was first cloned in human fetal astrocytes as an inducible gene by human immunodeficiency virus 1 (HIV)-1 and tumor necrosis factor-α (TNF-α) in 2002[@b3][@b4].Subsequently, clinical trial demonstrated that MTDH is a novel prognostic biomarker and high MTDH expression is associated with tumor progression and short overall survival (OS) time in breast cancer[@b5]. Similar results were found in other reproduction malignancies, such as epithelial ovarian cancer[@b6], cervical cancer[@b7] and endometrial cancer[@b8]. Two authors have performed meta-analysis to evaluate the clinicopathological and prognostic role of MTDH in squamous cell carcinoma and gastrointestinal cancers respectively. They concluded that high MTDH expression was remarkably correlated with lymph node metastasis, distant metastasis and short OS[@b9][@b10]. A review has extensively described the pleiotropic roles of MTDH in breast cancer[@b11]. Collectively, accumulating evidence suggested that MTDH might participate in the tumor metastasis process and can be regarded as therapeutic target of reproduction malignancies.

Up till now, no quantitative evaluation was performed. Because of the limited sample size, the conclusion of a single study lacks power of reliability. Hence, by reviewing published literature we performed a comprehensive meta-analysis in order to get a consistent and reliable conclusion and to cast light on the impact of MTDH expression on metastasis and survival status.

Results
=======

Literature identification and selection
---------------------------------------

In total, 1115 studies (791 in English and 324 in Chinese) were retrieved for our systematic review and subsequent meta-analysis after searching different databases. After removing duplicates, titles and abstracts of the remained 765 papers were prudently screened, among which 74 studies were obtained as they evaluated the role of MTDH/LYRIC/AEG-1/3D3 in female reproduction malignancies. Meanwhile, a total of 55 potentially relevant papers were excluded as they were against the inclusion criteria of our meta-analysis, of which three studies only investigated the gene expression of MTDH in breast and ovarian cancer. Two studies[@b12][@b13] which only provided survival curve but failed to calculate HR value were excluded from meta-analysis. They were included in the systematic review. Another 50 studies were excluded for lacking survival data or using cell lines to explore the impact of MTDH on biological characteristics, mechanisms and pathways of reproduction malignancies. Finally, a total of 19 studies (17 English articles and 2 Chinese articles)[@b5][@b6][@b7][@b8][@b14][@b15][@b16][@b17][@b18][@b19][@b20][@b21][@b22][@b23][@b24][@b25][@b26][@b27][@b28] published from 2008 to 2016 were included in our meta-analysis ([Fig. 1](#f1){ref-type="fig"}).

Characteristics of included literature
--------------------------------------

The 19 studies included in our meta-analysis analyzed the correlation of MDTH levels with clinicopathological parameters and survival outcomes in 2483 female reproduction malignancies patients. Among them 8 studies were about breast cancer[@b5][@b14][@b15][@b16][@b21][@b23][@b25][@b28], while 7 were about ovarian cancer[@b6][@b17][@b18][@b20][@b22][@b26][@b27], 3 about cervical cancer[@b7][@b19][@b24] and 1 about endometrial cancer[@b8].

A large proportion of these trails were performed in China and the number of patients ranged from 60 to 225. As for inclusion criteria, all the samples of included studies were tissues and their MTDH expression was examined by immunohistochemical (IHC). Eleven studies[@b5][@b6][@b8][@b15][@b16][@b17][@b18][@b21][@b23][@b25][@b26] defined staining index (SI) ≥ 4 as cut-off value of positive expression while the other 8 studies[@b7][@b14][@b19][@b20][@b22][@b24][@b27][@b28] did not. The follow-up time ranged from 36 to 180 months.

Data of distant metastasis were available in 8 studies[@b5][@b14][@b15][@b16][@b17][@b19][@b23][@b25][@b28] and data of lymph node metastasis were found in 12 studies[@b5][@b7][@b8][@b15][@b16][@b17][@b19][@b23][@b25][@b26][@b27][@b28]. For survival analysis, 14 studies[@b5][@b6][@b7][@b8][@b14][@b16][@b17][@b18][@b20][@b23][@b24][@b25][@b26][@b27] examined the association of MTDH expression with mortality and 8 studies[@b6][@b8][@b16][@b20][@b24][@b25][@b27][@b28] were available for disease-free survival (DFS). The concomitant variables of multivariate analysis were list in [](#t1){ref-type="table"}[Table 2](#t2){ref-type="table"}. Further details on characteristics of the included studies were shown in [Table 1](#t1){ref-type="table"} and [Table 2](#t2){ref-type="table"}.

Meta-analysis
-------------

### Breast cancer

Eight studies[@b5][@b14][@b15][@b16][@b21][@b23][@b25][@b28] with a total of 1167 breast carcinoma cases examined the relationship between MTDH and metastasis as well as survival status. Five studies[@b5][@b14][@b16][@b23][@b25] presented mortality information on MTDH expression, with a pooled HR of 2.728 (95% CI: 2.027--3.671, *P* \< 0.001) ([Fig. 2A](#f2){ref-type="fig"}, [Table 3](#t3){ref-type="table"}). As their heterogeneity was weak (*I*^*2*^ = 7.8%, *P* = 0.362), the fixed effects model was applied. Four studies[@b16][@b23][@b25][@b28] assessed the association of MTDH with DFS. Its pooled HR was 2.966 (95% CI: 1.997--4.405, *P* \< 0.001) ([Fig. 2B](#f2){ref-type="fig"}, [Table 3](#t3){ref-type="table"}) and no evidence of heterogeneity was found (*I*^*2*^ = 0.0%; *P* = 0.948). Seven studies[@b5][@b14][@b16][@b19][@b23][@b25][@b28] reported data on MTDH expression and distant metastasis in breast cancer. The pooled OR was 3.480(95% CI: 2.342--5.170, *P* \< 0.001) ([Fig. 2C](#f2){ref-type="fig"}, [Table 3](#t3){ref-type="table"}), and the heterogeneity was not significant (*I*^*2*^ = 0.0%; *P* = 0.710). Six studies[@b5][@b15][@b16][@b23][@b25][@b28] examined the correlation of MTDH with lymph node metastasis. Moderate heterogeneity was observed (*I*^*2*^ = 38.8%; *P* = 0.147) and the pooled fixed effects HR was 1.880 (95% CI: 1.433--2.465; *P* \< 0.001) ([Fig. 2D](#f2){ref-type="fig"}, [Table 3](#t3){ref-type="table"}). The above results indicated that high MTDH expression can lead to tumor metastasis and poor prognosis for females who suffered breast cancer.

### Ovarian cancer

Seven studies[@b6][@b17][@b18][@b20][@b22][@b26][@b27], with a total of 514 female cases, concluded that MTDH was a poor predictor for ovarian cancer. Six studies[@b6][@b17][@b20][@b22][@b26][@b27] with mortality data had a high heterogeneity of (*I*^*2*^ = 92.5%; *P* \< 0.001), and the pooled HR was 4.525(95% CI: 1.763--11.618, *P* \< 0.001) ([Fig. 3A](#f3){ref-type="fig"}, [Table 3](#t3){ref-type="table"}). Therefore random effects model was used. The pooled HR was 2.817(95% CI: 0.957--8.292, *P* = 0.060) ([Fig. 3B](#f3){ref-type="fig"}, [Table 3](#t3){ref-type="table"}) for those 3 studies[@b6][@b20][@b27] which described the DFS data. Significant high heterogeneity was observed and a random effects model was also used (*I*^*2*^ = 93.5%; *P* \< 0.001) for these 3 studies. There were another 3 studies[@b17][@b26][@b27] with 336 ovarian cancer cases examining the association of MTDH overexpression with lymph node metastasis. The pooled effects OR was 5.328 (95% CI: 1.870--15.175, *P* = 0.002) ([Fig. 3C](#f3){ref-type="fig"}, [Table 3](#t3){ref-type="table"}). Since the inter-study heterogeneity was moderate (*I*^*2*^ = 55.1%; *P* = 0.108), we applied the random-effects model.

### Cervical cancer

Three studies[@b7][@b19][@b24] with a number of 390 female cases described MTDH as the predictor of tumor deterioration in cervical cancer. Two of the studies[@b7][@b24] stated a high mortality for patients with an overexpression of MTDH and we calculated a combined HR. The result was 2.524 (95% CI: 1.152--5.529, *P* \< 0.001) ([Fig. 4A](#f4){ref-type="fig"}, [Table 3](#t3){ref-type="table"}). However, the inter-study heterogeneity was moderate (*I*^*2*^ = 66.5%; *P* = 0.084), thus we performed the random-effects model. To examine the relationship between high tumoral MTDH expression and lymph node metastasis in cervical cancer, we combined OR from two studies[@b7][@b19] and the pooled OR was 4.732 (95% CI: 1.922--11.652, *P* = 0.001) ([Fig. 4B](#f4){ref-type="fig"}, [Table 3](#t3){ref-type="table"}). No significant inter-study heterogeneity was observed (*I*^*2*^ = 0.9%; *P* = 0.315).

### Meta-analysis of all the included cancers

Based on 14 studies that examined the association of MTDH with mortality of various female reproduction cancers, the pooled random effects HR was 3.647 (95% CI: 2.385--5.577, *P* \< 0.001) ([Fig. S1A](#S1){ref-type="supplementary-material"}, [Table 3](#t3){ref-type="table"}). There was significant high heterogeneity when all studies were combined (*I*^*2*^ = 83.9%; *P* \< 0.001). A total of 8 studies[@b6][@b8][@b16][@b20][@b23][@b25][@b27][@b28] evaluated the relevance of MTDH expression with DFS in female reproduction cancers, with the overall random effects HR of 2.917(95% CI: 1.715--4.963, *P* \< 0.001) ([Fig. S1B](#S1){ref-type="supplementary-material"}, [Table 3](#t3){ref-type="table"}). The heterogeneity was high (*I*^*2*^ = 83.9%; *P* \< 0.001). The pooled results from these studies indicated MTDH overexpression in reproduction cancers can cause a short lifespan for patients. Besides, 8 studies[@b5][@b14][@b16][@b17][@b19][@b23][@b25][@b28] examined the association of MTDH with distant metastasis and 12 studies[@b5][@b7][@b8][@b15][@b16][@b17][@b19][@b23][@b25][@b26][@b27][@b28] examined the association of MTDH with lymph node metastasis. The overall fixed effects OR was 3.739 (95% CI: 2.558--5.466, *P* \< 0.001) ([Fig. S1C](#S1){ref-type="supplementary-material"}, [Tables 3) and 2.696](#t3){ref-type="table"} (95% CI: 1.874--3.879, *P* \< 0.001) ([Fig. S1D](#S1){ref-type="supplementary-material"}, [Table 3](#t3){ref-type="table"}), respectively. Both pooled results showed that MTDH in female reproduction cancers can be regarded as an unfavorable predictor in tumor metastasis. No significant heterogeneity was found when examining the relationship between MTDH and distant metastasis (*I*^*2*^ = 0.0%; *P* = 0.619), while moderate heterogeneity can be found in the studies related to lymph node metastasis (*I*^*2*^ = 53.2%; *P* = 0.015).

Sensitivity analysis
--------------------

After excluding every single study in order, the pooled HRs for mortality and ORs metastasis did not change significantly ([Fig. S2A,C,D](#S1){ref-type="supplementary-material"}). For DFS, the study published by Dong R[@b20] *et al*. significantly affected the pooled HR ([Fig. S1B](#S1){ref-type="supplementary-material"}). After eliminating the study published by Dong R[@b20] *et al*., the pooled HR changed from 2.641 (95% CI: 1.497--4.658, *P* = 0.001) to 3.300 (95% CI: 2.338--4.657, *P* \< 0.001) ([Fig. S3](#S1){ref-type="supplementary-material"}) and no heterogeneity was observed. For multiple cut-off value used in different studies, we conducted a sensitivity analysis including only 8 studies which used the same cut-off value (SI ≥ 4) for mortality analysis. The result was significant with an HR of 3.613 (95% CI: 2.806--4.653, *P* \< 0.001).

Publication bias
----------------

For the group with more than 10 studies, we performed Begg's test to assess publication bias. Our results showed that there was no evidence of publication bias in mortality ([Fig. 5A](#f5){ref-type="fig"}, *P* = 0.112). However, significant publication bias was observed for the studies concerned with lymph node metastasis ([Fig. 5B](#f5){ref-type="fig"}, *P* = 0.001). Trim and fill method was conducted to enroll missing studies. After enrolling missing studies, the pooled random-effects OR was 2.150 (95% CI: 1.465--3.155) ([Fig. S4](#S1){ref-type="supplementary-material"}). Due to the limited number of studies, publication bias was not examined for other group of meta-analysis.

Systematic review
-----------------

Two studies[@b12][@b13] provided survival curve but failed to calculate HR value were included in systematic review. Ward A[@b13] *et al*. showed that high MTDH expression was remarkably associated with short DFS in breast cancer (*P* = 0.0233) with a cohort of patients from public data (GSE1378). The study published by Liu P[@b12] *et al*. suggested that high MTDH level was significantly correlated with poor OS in triple negative breast cancer (*P* = 0.006), but no statistical significance was observed for DFS (*P* = 0.065).

Discussion
==========

Meta-analysis can enhance statistical power by quantitatively combining the results of multiple independent studies. As several studies have regarded MTDH as the potential biomarker which can indicate the metastasis and prognosis in malignancies, and as MTDH could miraculously induce breast cancer cells transferring to lung in mouse model, we carried out this comprehensive systematic review and meta-analysis based on published literature to thoroughly investigate the significance of MTDH in reproduction malignancies. Our results showed that MTDH, as a cell surface protein, is significantly associated with the mortality of patients with reproduction malignancies (HR = 3.647), including breast cancer (HR = 2.728), ovarian cancer (HR = 4.525), cervical cancer (HR = 2.524) and endometrial cancer (HR = 2.524). For DFS, significant result was observed in breast cancer (HR = 2.966) but not in ovarian cancer. Moreover, high MTDH expression remarkably increased the risk of distant metastasis (HR = 3.739) and lymph node metastasis (HR = 2.696) in reproduction malignancies. A strong association was observed between MTDH and metastasis as well as prognosis in clinical malignancies. The pooled results of those 8 studies[@b5][@b14][@b15][@b16][@b21][@b23][@b25][@b28] in breast cancer enrolled in our meta-analysis showed that high MTDH is remarkably correlated with high risk of metastasis and poor prognosis. Meanwhile, no significant heterogeneity was observed (P \> 0.05). According to the above evidences, MTDH is likely to be the fundamental material for tumor metastasis and can lead to poor prognosis in reproduction malignancies. For breast cancer, the results of our meta-analysis implied that MTDH might be a novel biomarker being applied to clinic.

Heterogeneity is one of possible factors impacting the pooled results of meta-analysis[@b29]. Heterogeneity was observed when we mixed all reproduction malignancies and calculated the combined effects of MTDH on mortality (*I*^*2*^ = 82.1%) and DFS (*I*^*2*^ = 80.7%). However, when we divided the included studies into different cancer types, no significant heterogeneity was found in breast cancer (P \> 0.05). Thus, the difference in cancer type might be one of the potential factors that caused inter-study heterogeneity. For ovarian cancer, the possible reasons of heterogeneity might be the selection of tissue and the computing method of HR. Of 7 studies in ovarian cancer, 3 studies[@b6][@b17][@b27] only selected epithelial ovarian cancer while other 4 studies[@b18][@b20][@b22][@b26] contained various types of ovarian cancer. Li C[@b18] *et al*. only analyzed the prognosis of patients with stages III--IV. The study published by Dong R[@b20] *et al*. only provided survival curve while the other studies offered HR value of multivariate analysis. To take all the heterogeneity described above into consideration, we pooled the HRs using random effects model. For the combination of those studies which didn't have statistically significant heterogeneity, a fixed effects model was used to acquire more accurate combined HR.

The unpublished studies or studies with negative results were not included in our meta-analysis, which might cause same bias and affect the pooled results. For publication bias, we performed Begg's test in the mortality and lymph node metastasis group. No obvious publication bias (*P* = 0.112) was observed in mortality group while significant publication bias was observed in lymph node metastasis group (*P* = 0.001). Thus, trim and fill method was conducted to enroll missing studies. However, the final result was not distinctly altered, which implied that the pooled result was stable and creditable. The results of sensitivity analysis indicated that our meta-analysis was stable for all the groups except DFS. For DFS, the result didn't change obviously after eliminating the study published by Dong R[@b20] *et al*. Meanwhile, the result of sensitivity analysis for studies using the same cut-off (SI ≥ 4) was similar to all studies of mortality group, which implied the reliability of our conclusion.

The current meta-analysis featured the following strengths. Firstly, we conducted a comprehensive search and extracted up-to-date published literatures. Secondly, all the included studies were with sufficient patients ( \> 50), which favorably avoided the effects of small sample. Thirdly, all the samples of the included studies were from tissues and their MTDH was examined by IHC, which ensured the homogeneity of our meta-analysis. Moreover, there was no significant heterogeneity when we pooled the studies in breast cancer. The strengths above immensely enhanced the reliability of our meta-analysis. Still, there were also a few limitations. Four studies[@b23][@b24][@b25][@b28] only provided survival cure rather than HR value, thus we had to extract HR value using the software Engauge Digitizer version 4.1, which might cause bias to accurate HR value. Meanwhile, different variables adjusted by multivariate analysis of each single study also affected the pooled HRs.

Recently, a number of studies have investigated the impact of MTDH in reproduction malignancies. They rifely concluded that MTDH was associated with specific biological characteristics and molecular pathways related to tumor deterioration, but the exact mechanism was still unclear. Chemoresistance/radioresistance might be one of the reasons related to poor prognosis. MTDH could mediate drug resistance in various cancers[@b30] as suggested by Meng *et al*. For reproduction malignancies, it was reported that inhibition of MTDH increases cancer cells' sensitivity to chemotherapy drugs, such as AZD6244, tumor necrosis factor-a-related apoptosis-inducing ligand (TRAIL) and HDAC inhibitor LBH589[@b31][@b32][@b33]. Interestingly, Zhao Y *et al*. confirmed that MTDH induces radioresistance and inhibits apoptosis in cervical cancer cells[@b34]. MTDH also acts as a regulator for tumor progression and high MTDH expression promotes the proliferation, invasion and metastasis of cancer cell in reproduction malignancies by interacting with staphylococcal nuclease domain-containing 1, Ha-ras protein or RNA[@b34][@b35][@b36][@b37][@b38][@b39]. According to the published studies, MTDH might exert its powerful regulatory functions in reproduction malignancies via molecular pathways: PI3K-Akt[@b37], protective autophagy[@b40], NF-κB[@b36][@b41][@b42] and PTEN/AKT[@b21][@b43].Collectively, MTDH plays a vital role in tumor progression. Thus, down-regulating of MTDH might be an effective method to lengthen survival time and reduce mortality in reproduction malignancies.

In conclusion, our meta-analysis suggests that high MTDH expression increases risk of distant metastasis and lymph node metastasis in reproduction malignancies. Furthermore, high MTDH expression is remarkably associated with high mortality in reproduction malignancies. Specifically, the results our meta-analysis indicates that high MTDH expression is strongly associated with high risk of tumor metastasis and worse prognosis in breast cancer. Thus, our study provides evidence that MTDH might be a potential novel biomarker effectively reflecting metastasis status and prognosis of breast cancer patients, which might help to formulate a better therapy for individual patient. Simultaneously, to enhance the creditability of our meta-analysis, more prospective studies with large samples are needed.

Methods
=======

Literature search strategy and selection
----------------------------------------

A comprehensive electronic literature search was conducted using the following English databases and Chinese databases: PubMed, Wiley Online Library, Science Direct, EMBASE, Cochrane Central Register of Controlled Trials, ISI Web of Science, China National Knowledge Infrastructure (CNKI) and Wanfang database. The literature search strategy was as follow: "metadherin OR MTDH OR astrocyte elevated gene-1 OR AEG1 OR AEG-1 OR LYRICOR LYRIC/3D3 OR 3D3″\[All Fields\] AND "tumor OR tumour OR cancer OR carcinoma OR neoplasm OR neoplastic OR malignancy"\[All Fields\] AND "prognosis OR prognostic OR survival OR survivance OR mortality OR outcome OR predict\* OR follow-up" \[All Fields\]. The search was not finished until September 21, 2016.

Firstly, all the titles and abstracts of each literature found by the search strategy were imported to EndNote X7. Then, two independent authors (Yongbin Hou and Liyi Hu) screened out the eligible literature which investigated the association between MTDH/LYRIC/AEG-1/3D3 expression and clinicopathological features as well as survival outcomes in patients with female reproduction cancers. Finally, full-text articles of eligible literatures were reviewed in detail, including references cited in the literature, according to our inclusion and exclusion criteria.

The detailed inclusion criteria were listed in [Table 4](#t4){ref-type="table"}. The exclusion criteria were listed as follow: (1) animal or cell line trails, case reports, reviews and meta-analysis; (2) studies failed to estimated HRs/ORs and its 95% CI. In addition, we attempted to contact authors, if possible, to obtain raw data for the studies whenever inadequate data were provided to estimate HRs/ORs and its 95% CI. For the studies including overlapped patients, we only included the most complete studies in our meta-analysis. If there were controversies, the two authors would solve the problem by discussion.

Data extraction
---------------

The following information was extracted from each study by two independent authors (Yonghua Mi and Yongbin Hou) using a standard excel form: first author; year of publication; types of cancer; source and number of patients; detected method for MTDH/LYRIC/AEG-1/3D3; cut-off value for positive MTDH/LYRIC/AEG-1/3D3 expression; longest follow-up time. For metastasis status of included studies, ORs as well as their 95% CI were extracted. For survival analysis, HRs along with their 95% CI and P value were extracted. If the results multivariate analysis were available, the HRs/ORs values of multivariate analysis and concomitant variables were extracted. Otherwise, the HRs/ORs of univariate analysis (univariate cox regression/logistic regression, survival curve or available data to estimate HR/OR) were extracted. Subsequently, all the data were double-checked by a third author (Liyi Hu) and controversies were solved by discussion.

Statistical analysis
--------------------

For the meta-analysis, we stratified the results by the type of reproduction carcinoma. To describe the intensity of relationship between MTDH and clinical outcomes in reproduction malignancies patients, HR value and OR value as well as their 95% CI were used. With a standard excel form, the HR value and OR value of each single study were extracted. For HR and OR value, we extracted the relevant data directly if they were given in the studies. As for those statistical variables which were indirectly stated, we estimated their values on the basis of available data or Kaplan-Meier curves by methods of Jayne F Tierney[@b44] described.

Subsequently, the HRs (ORs) values were quantificationally combined on STATA12.0 (STATA Corp., College,Texas). For heterogeneity analysis, the Cochran Q test and the Higgins *I*^*2*^ statistical method[@b29] were carried out. When statistically significant heterogeneity was observed (*P* \< 0.05), the random-effects model[@b45] was used to combine relevant data. Otherwise, the fixed-effects model[@b46] was used (when *P* \> 0.05). The *I*^*2*^ statistic was regarded as a quantitative measure of the degree of inconsistency among the studies. When *I*^*2*^ = 0, there was no heterogeneity. The larger the percentage, the increasing heterogeneity[@b47]. As for the consistency of our presentation, an *I*^*2*^ value of 1 to 25%, 25 to 75%, 75to 100% was considered low heterogeneity, moderate heterogeneity and high heterogeneity, respectively. A statistically significant HR (OR) \> 1 suggested that high MTDH indicated worse survival outcomes and increased the risk of metastasis. *P* values less than 0.05 were considered to be statistically significant.

Concerning the positive results being more likely to published, publication bias was assessed by Begg's test with funnel plots when the meta-analysis included 10 or more studies. A symmetrical inverted funnel implied that there was no significant publication bias among included studies. Trim and fill method was conducted to reduce publication bias if statistically significant publication bias was observed. Furthermore, sensitivity analysis was conducted by eliminating single study successively and the rest studies was pooled to examine the stability of the results. Also, sensitivity analysis was performed in studies of mortality which employed the same cut-off value (SI ≥ 4). The current study is a meta-analysis which gained ethical approval and all the procedures of this study followed PRISMA guidelines[@b48].
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###### Main characteristic of included studies.

  Author              Year            Cancer types             Source of patients   Cases   Samples   Method   Cut-off value for positive         Follow-up (Months)
  ------------------ ------ --------------------------------- -------------------- ------- --------- -------- ---------------------------- ---------------------------------
  Li J[@b5]           2008            breast cancer                  China           225    tissue     IHC               SI ≥ 4             80[\*](#t1-fn1){ref-type="fn"}
  Hu GH[@b14]         2009            breast cancer                 America          170    tissue     IHC                 NR               180[\*](#t1-fn1){ref-type="fn"}
  Su P[@b15]          2010            breast cancer                  China           162    tissue     IHC               SI ≥ 4                            /
  Li C[@b16]          2011   breast cancer (triple-negative)         China           125    tissue     IHC               SI ≥ 4             70[\*](#t1-fn1){ref-type="fn"}
  Tokunaga E[@b23]    2014            breast cancer                  Japan           195    tissue     IHC               SI ≥ 4                           119
  Du C[@b21]          2014            breast cancer                  China           118    tissue     IHC               SI ≥ 4                            /
  Tan LS[@b25]        2015   breast cancer (triple-negative)         China           112    tissue     IHC               SI ≥ 4                           90
  Meng F[@b6]         2011      epithelial ovarian cancer            China           81     tissue     IHC               SI ≥ 4                           78
  Li C[@b17]          2011      epithelial ovarian cancer            China           157    tissue     IHC               SI ≥ 4                            /
  Li C[@b18]          2012           ovarian cancer                  China           101    tissue     IHC               SI ≥ 4                           96
  Li C[@b22]          2014           ovarian cancer                  China           102    tissue     IHC               SI ≥ 3                          \>36
  Dong R[@b20]        2014           ovarian cancer                  China           76     tissue     IHC               SI ≥ 2                           60
  Zhou B[@b26]        2015           ovarian cancer                  China           73     tissue     IHC               SI ≥ 4                           80
  Long M[@b19]        2013           cervical cancer                 China           220    tissue     IHC               SI ≥ 3                            /
  Huang K[@b7]        2013           cervical cancer                 China           90     tissue     IHC        positive rate ≥ 40%       80[\*](#t1-fn1){ref-type="fn"}
  Song EL[@b24]       2014           cervical cancer                 China           80     tissue     IHC         intensity ≥ 17.4%        60[\*](#t1-fn1){ref-type="fn"}
  Song HT[@b8]        2010         endometrial cancer                China           174    tissue     IHC               SI ≥ 4                           76
  Wang Y[@b27]        2016           ovarian cancer                  China           162    tissue     IHC               SI ≥ 3                           78
  Jin P[@b28]         2013            breast cancer                  China           60     tissue     IHC               SI ≥ 2             125[\*](#t1-fn1){ref-type="fn"}

^\*^Extracted from survival curve; IHC: immunohistochemistry; SI: staining index = staining intensity × proportion of positive tumor.

###### The HRs/ORs value and concomitant variables of included studies.

  Author              Year   Distant metastasis (OR/HR)   lymph node metastasis (OR/HR)           Survival analysis                 HR (95% CI)            P     Concomitant variables
  ------------------ ------ ---------------------------- ------------------------------- ------------------------------------ ------------------------ --------- --------------------------------------------------------------------------------------------------------------------------------------------------------------
  Li J[@b5]           2008     9.930 (2.200--44.820)          1.714 (0.999--2.943)                      OS (M)                  2.906 (1.810--4.668)    \<0.001  T classification, N classification.
  Hu GH[@b14]         2009   4.280 (1.320--13.900) (M)                  /                              CSS (U)                 8.300 (1.894--36.376)     0.005   ER, PR, HER2, p53 and tumor size.
  Su P[@b15]          2010               /                    1.094 (0.587--2.038)                        /                              /                 /      
  Li C[@b16]          2011      3.875 (1.647--9.118)          3.188 (1.524--6.671)                      OS (M)                  3.484 (1.505--8.062)    \<0.001  tumor size, lymphatic and venous invasion, lymph node status.
                                                                                                       DFS (M)                  3.032 (1.388--6.622)     0.014    
  Tokunaga E[@b23]    2014     2.39 (1.08--5.01) (M)          1.771 (0.861--3.642)                     DFS (M)                  3.450 (1.690--6.840)     0.001   tumor size, nodal involvement, nuclear grade, lymphovascular invasion, ER, PR, HER2.
                                                                                          OS (U)[a](#t2-fn1){ref-type="fn"}     1.950 (1.173--3.241)     0.01     
  Tan LS[@b25]        2015      2.604 (1.084--6.257)          3.900 (1.724--8.821)        OS (U)[a](#t2-fn1){ref-type="fn"}     3.140 (1.230--8.010)     0.017    
                                                                                          DFS (U)[a](#t2-fn1){ref-type="fn"}    2.540 (1.140--5.660)     0.023    
  Meng F[@b6]         2011               /                              /                               OS (M)                 5.573 (2.199--14.124)    \<0.001  FIGO stage, residual tumor, histological type.
                                                                                                       DFS (M)                  3.982 (1.913--8.286)    \<0.001   
  Li C[@b17]          2011   8.541 (2.561--37.461) (M)      9.581 (2.613--23.214) (M)                     /                              /                 /     FIGO stage, residual tumor size.
  Li C[@b18]          2011               /                              /                               OS (M)                 19.380 (7.518--34.192)   \<0.001  age, lymph node metastasis, histopathological differentiation, serum CA-125 level, cytoreduction, FIGO stage, residual tumour size, chemotherapy resistance.
  Li C[@b22]          2014               /                              /                               OS (M)                  2.673 (1.445--4.867)     0.002   age, primary malignancies, extent of disease, ascites, size, time to diagnosis.
  Dong R[@b20]        2014               /                              /                 OS (U)[a](#t2-fn1){ref-type="fn"}     1.280 (1.004--1.631)     0.046    
                                                                                          DFS (U)[a](#t2-fn1){ref-type="fn"}    1.200 (0.989--1.456)     0.065    
  Zhou B[@b26]        2015               /                   10.588 (1.312--85.438)                     OS (M)                  3.037 (1.067--8.670)     0.036   age, histological type, differentiation degree, lymph node metastasis, clinical stage.
  Huang K[@b7]        2013               /                    4.050 (1.565--10.481)                     OS (M)                  4.021 (1.734--8.283)     0.027   age, tumor size, histological classification, clinical stage, pathological grade, lymph node metastasis.
  Song EL[@b24]       2014               /                              /                 OS (U)[a](#t2-fn1){ref-type="fn"}     1.790 (1.105--2.900)     0.018    
  Long M[@b19]        2013     6.781 (0.388--118.631)        18.616 (1.110--312.323)                      /                              /                 /      
  Song HT[@b8]        2010               /                    3.929 (1.437--10.743)                     OS (M)                 4.960 (1.774--13.869)     0.002   FIGO stage, lymphatic and venous invasion, histological type.
                                                                                                       DFS (M)                  3.573 (1.499--8.518)     0.004    
  Wang Y[@b27]        2016               /                    2.500 (1.101--5.676)                      OS (M)                 8.644 (4.255--17.556)    \<0.001  FIGO stage, residual tumor.
                                                                                                       DFS (M)                  5.132 (2.943--8.949)    \<0.001   
  Jin P[@b28]         2013     4.429 (1.373--14.283)          1.699 (1.145--4.230)        DFS (U)[a](#t2-fn1){ref-type="fn"}    2.710 (1.070--6.900)     0.036    

HR: hazard ratio; OR: odds ratios; OS: overall survival; CSS: cancer-specific survival; DFS: disease-free survival; M: multivariate analysis; U: univariate analysis;

^a^extracted from survival curve; ER: estrogen receptor; PR: progesterone receptor; HER2: human epidermal growth factor receptor-2; FIGO: International Federation of Gynecology and Obstetrics.

###### Meta-analysis of HRs/ORs evaluating the association of MTDH with tumor metastasis and prognosis.

  Groups                                  Studies   Pooled HR/OR (95% CI)     *P*     Effect model           Heterogeneity
  -------------------------------------- --------- ----------------------- --------- -------------- --------------------------------
  ***Mortality (OS + CSS)***                                                                        
  Overall                                   14      3.647 (2.385--5.577)    \<0.001      random      *I*^*2*^ = 83.9%; *P* \< 0.001
  Breast cancer                              5      2.728 (2.027--3.671)    \<0.001      fixed        *I*^*2*^ = 7.8%; *P* = 0.362
  Ovarian cancer                             6      4.525 (1.763--11.618)    0.002       random      *I*^*2*^ = 92.8%; *P* \< 0.001
  Cervical cancer                            2      2.524 (1.152--5.529)     0.021       random      *I*^*2*^ = 66.5%; *P* = 0.084
  ***DFS***                                                                                         
  Overall                                    8      2.917 (1.715--4.963)    \<0.001      random      *I*^*2*^ = 83.9%; *P* \< 0.001
  Breast cancer                              4      2.966 (1.997--4.405)    \<0.001      fixed        *I*^*2*^ = 0.0%; *P* = 0.948
  Ovarian cancer                             3      2.817 (0.957--8.292)     0.060       random      *I*^*2*^ = 93.5%; *P* \< 0.001
  *D***istant metastasis (Yes/No)**                                                                 
  Overall                                    8      3.739 (2.558--5.466)    \<0.001      fixed        *I*^*2*^ = 0.0%; *P* = 0.619
  Breast cancer                              7      3.480 (2.342--5.170)    \<0.001      fixed        *I*^*2*^ = 0.0%; *P* = 0.710
  ***Lymph node metastasis (Yes/No)***                                                              
  Overall                                   12      2.696 (1.874--3.879)    \<0.001      random      *I*^*2*^ = 53.2%; *P* = 0.015
  Breast cancer                              6      1.880 (1.433--2.465)    \<0.001      fixed       *I*^*2*^ = 38.8%; *P* = 0.147
  Ovarian cancer                             3      5.328 (1.870--15.175)    0.002       random      *I*^*2*^ = 55.1%; *P* = 0.108
  Cervical cancer                            2      4.732 (1.922--11.652)    0.001       fixed        *I*^*2*^ = 0.9%; *P* = 0.315

HR: hazard ratio; OR: odds ratios; OS: overall survival; CSS: cancer-specific survival; DFS: disease-free survival.

###### Inclusion criteria for eligible studies.

  ----------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study types       observational studies (prospective or retrospective)
  Language          English, Chinese
  Databases         PubMed, Wiley Online Library, Science Direct, EMBASE, Cochrane Central Register of Controlled Trials, ISI Web of Science, China National Knowledge Infrastructure (CNKI) and Wanfang database
  Tumor type        female reproduction malignancies
  Sample            tissue
  Sample size       \>50
  Tumor stage       unlimited
  Examined method   IHC
  Follow-up         unlimited
  Outcome           OS, CSS, DFS and metastasis
  Analysis          presenting the HRs/ORs value and its 95% CIs, Kaplan-Meier survival curves or relevant data to calculate HRs/ORs
  ----------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

IHC: immunohistochemistry; OS: overall survival; CSS: cancer-specific survival; DFS: disease-free survival.
